18.02.2019 • News

Mitsui, ISK Take Stakes in Brazil’s Ourofino

Mitsui, ISK Take Stakes in Brazil’s Ourofino (c) Ourofino
Mitsui, ISK Take Stakes in Brazil’s Ourofino (c) Ourofino

Japanese companies Mitsui & Co. and Ishihara Sangyo Kaisha (ISK) have signed a binding agreement to jointly acquire a 25% stake in Brazilian agrochemical company, Ouro Fino Quimica. Mitsui will take a 20% share of Ourofino, with ISK taking 5%.

Completion of the transaction is subject to customary conditions and regulatory approval. The companies have not revealed financial details.

Located in Uberaba, Minas Gerais, Ourofino manufactures a range of agrochemicals, including fungicides, herbicides and insecticides.

Mitsui said it intends with ISK to contribute to expanding Ourofino’s business in Brazil, which is the world’s largest market for crop protection products, accounting for about 20% of global demand. Ourofino will benefit from access to Mitsui’s assets around the world and will include ISK’s products, which include herbicides, fungicides, insecticides and nematicides, into its portfolio.

As part of its medium-term management plan, Mitsui has identified nutrition and agriculture as one of its key new growth areas. The Tokyo-headquartered group distributes agrochemicals and agricultural supplies in Europe through wholly owned subsidiary Mitsui AgriScience International Europe and in the US through its fully owned biopesticides division Certis USA.

Company

Logo:

Mitsui Chemicals Europe GmbH

Oststr. 34
40211 Düsseldorf
Germany

Company contact







Interview

The UK Chemical Supply Chain
Trade and Competitiveness

The UK Chemical Supply Chain

The CBA, led by CEO Tim Doggett, is steering the UK chemical supply chain through trade uncertainty, sustainability pressures and logistics challenges, as he explains in this interview with CHEManager.

Expert Insights

ADCs for Precision Cancer Therapy
Comprehensive Insights into Antibody–Drug Conjugates

ADCs for Precision Cancer Therapy

Explore how antibody-drug conjugates are reshaping precision cancer therapy and discover what it takes to successfully develop, manufacture, and scale these complex biologics.

most read